Collaborations

Dyax Corp. and CSIRO form joint antibody discovery collaboration in oncology

Published in Cancer Gene Therapy Week, December 25th, 2006

Dyax Corp. (DYAX) and the Division of Molecular and Health Technologies of the Commonwealth Scientific and Industrial Research Organisation (CSIRO), Australia's national scientific research agency, announced that they have entered into a collaboration for the discovery and development of therapeutic antibodies to treat cancer.

During the discovery phase of the collaboration, Dyax will utilize its proprietary antibody libraries to screen for clinical candidates, and CSIRO will provide reagents and in vitro assays, as well as certain in vivo and preclinical development work. Upon successful completion of the discovery work, CSIRO and Dyax will have the option to advance...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Gene Therapy Week

Source: Cancer Gene Therapy Week (2006-12-25)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry